Mega Cap
Drug Manufacturers - General
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Eli Lilly
LLY
$1.1T
| $1.1T | $1,233.66 | 1.06% |
|
2
Johnson & Johnson
JNJ
$658B
| $658B | $273.14 | 0.04% |
|
3
AbbVie
ABBV
$470B
| $470B | $265.79 | 0.48% |
|
4
Merck
MRK
$386B
| $386B | $156.45 | 3.84% |
|
5
Novartis
NVS
$304B
| $304B | $159.98 | 1.24% |
|
6
AstraZeneca
AZN
$263B
| $263B | $169.66 | 1.77% |
|
7
Amgen
AMGN
$239B
| $239B | $442.24 | 0.36% |
|
|
NVO
8
Novo Nordisk
NVO
$215B
| $215B | $48.66 | 3.71% |
|
Mega Cap Drug Manufacturers - General Stocks at a Glance
Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.
There are 8 mega cap Drug Manufacturers - General stocks — companies in the Drug Manufacturers - General industry with a market cap over $200B — worth a combined $3.63T.
The largest by market cap are Eli Lilly (LLY) at $1.1T, Johnson & Johnson (JNJ) at $658B and AbbVie (ABBV) at $470B.
Among institutional investors, Eli Lilly (LLY) drew the most net new fund positions in Q2 2026: 412 funds opened new positions, taking total fund holders up 233 (5.3%) quarter-over-quarter.
- Combined market cap: $3.63T across 8 stocks.
- Mega Cap: market cap over $200B.
- Largest constituent: Eli Lilly (LLY), $1.1T market cap.
- Most net new fund positions in Q2 2026: Eli Lilly (LLY), +233 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.